Phase 3 Chronic Kidney Disease Trial, Recruiting NCT05931276 Sponsor: VA Office of Research and Development Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT05931276
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are currently receiving hemodialysis (a kidney treatment that filters your blood using a machine)
  • You have been prescribed one of these heart/blood pressure medications through a VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, or bisoprolol

Who may not be able to join:

  • You have difficulty making your own medical decisions
  • You have a history of asthma and are NOT currently taking the medication carvedilol
  • You have a known allergy or bad reaction to any ingredient in either of the study drugs
  • Your doctor is not willing to write a new medication order if you are assigned to a treatment group
  • You are unable to give consent yourself, as a family member or other person cannot give consent on your behalf

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
22 May 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Time to major cardiovascular event

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov